How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
33
VTAK Quote, Financials, Valuation and Earnings
Last price:
$2.02
Seasonality move
:
-32.83%
Day range:
$2.05 - $2.19
52-week range:
$1.49 - $15.68
Dividend yield:
0%
P/E ratio:
0.40x
P/S ratio:
9.83x
P/B ratio:
0.38x
Volume:
17.9K
Avg. volume:
31.1K
1-year change:
-73.81%
Market cap:
$2.6M
Revenue:
$420K
EPS (TTM):
-$34.94
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
VTAK
Catheter Precision, Inc.
|
$310K | -$0.20 | 118.75% | -11.57% | -- |
|
CATX
Perspective Therapeutics, Inc.
|
$231.1K | -$0.35 | -57.02% | -40.33% | $12.3077 |
|
INFU
InfuSystem Holdings, Inc.
|
$36.7M | $0.05 | 8.36% | 39.86% | $14.20 |
|
PMI
Picard Medical
|
-- | -- | -- | -- | -- |
|
VNRX
VolitionRX Ltd.
|
$714.1K | -$0.04 | 227.21% | -28.83% | $2.20 |
|
XTNT
Xtant Medical Holdings, Inc.
|
$30.8M | -- | -2.42% | -100% | $1.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
VTAK
Catheter Precision, Inc.
|
$2.09 | -- | $2.6M | 0.40x | $0.00 | 0% | 9.83x |
|
CATX
Perspective Therapeutics, Inc.
|
$2.5600 | $12.3077 | $190.3M | -- | $0.00 | 0% | 173.58x |
|
INFU
InfuSystem Holdings, Inc.
|
$8.11 | $14.20 | $164.9M | 31.01x | $0.00 | 0% | 1.22x |
|
PMI
Picard Medical
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
VNRX
VolitionRX Ltd.
|
$0.26 | $2.20 | $31.9M | -- | $0.00 | 0% | 17.82x |
|
XTNT
Xtant Medical Holdings, Inc.
|
$0.64 | $1.50 | $88.9M | 62.25x | $0.00 | 0% | 0.69x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
VTAK
Catheter Precision, Inc.
|
68.63% | 0.156 | 537.37% | 0.41x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.042 | 1.3% | 8.47x |
|
INFU
InfuSystem Holdings, Inc.
|
30.8% | 4.042 | 11.73% | 1.35x |
|
PMI
Picard Medical
|
-- | 0.000 | -- | -- |
|
VNRX
VolitionRX Ltd.
|
-48.16% | 2.723 | 15.4% | 0.04x |
|
XTNT
Xtant Medical Holdings, Inc.
|
39.2% | 3.120 | 35.76% | 1.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
VTAK
Catheter Precision, Inc.
|
-$320K | -$3M | -79.27% | -192.05% | -1336.73% | -$2.2M |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
INFU
InfuSystem Holdings, Inc.
|
$20.3M | $3.8M | 6.43% | 9.93% | 10.45% | $8.4M |
|
PMI
Picard Medical
|
-- | -- | -- | -- | -- | -- |
|
VNRX
VolitionRX Ltd.
|
$318.2K | -$5.1M | -- | -- | -813.17% | -$3.5M |
|
XTNT
Xtant Medical Holdings, Inc.
|
$22M | $2.5M | 2.15% | 3.78% | 7.64% | $4.2M |
Catheter Precision, Inc. vs. Competitors
-
Which has Higher Returns VTAK or CATX?
Perspective Therapeutics, Inc. has a net margin of -1037.17% compared to Catheter Precision, Inc.'s net margin of -12425.36%. Catheter Precision, Inc.'s return on equity of -192.05% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital VTAKCatheter Precision, Inc.-141.59% -$1.70 $21.3M CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About VTAK or CATX?
Catheter Precision, Inc. has a consensus price target of --, signalling upside risk potential of 1718.24%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 380.77%. Given that Catheter Precision, Inc. has higher upside potential than Perspective Therapeutics, Inc., analysts believe Catheter Precision, Inc. is more attractive than Perspective Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VTAKCatheter Precision, Inc.0 0 0 CATXPerspective Therapeutics, Inc.12 1 0 -
Is VTAK or CATX More Risky?
Catheter Precision, Inc. has a beta of -1.392, which suggesting that the stock is 239.195% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.
-
Which is a Better Dividend Stock VTAK or CATX?
Catheter Precision, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catheter Precision, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VTAK or CATX?
Catheter Precision, Inc. quarterly revenues are $226K, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Catheter Precision, Inc.'s net income of -$2.3M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Catheter Precision, Inc.'s price-to-earnings ratio is 0.40x while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catheter Precision, Inc. is 9.83x versus 173.58x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VTAKCatheter Precision, Inc.9.83x 0.40x $226K -$2.3M CATXPerspective Therapeutics, Inc.173.58x -- $209K -$26M
-
Which has Higher Returns VTAK or INFU?
InfuSystem Holdings, Inc. has a net margin of -1037.17% compared to Catheter Precision, Inc.'s net margin of 6.19%. Catheter Precision, Inc.'s return on equity of -192.05% beat InfuSystem Holdings, Inc.'s return on equity of 9.93%.
Company Gross Margin Earnings Per Share Invested Capital VTAKCatheter Precision, Inc.-141.59% -$1.70 $21.3M INFUInfuSystem Holdings, Inc.55.65% $0.11 $80.2M -
What do Analysts Say About VTAK or INFU?
Catheter Precision, Inc. has a consensus price target of --, signalling upside risk potential of 1718.24%. On the other hand InfuSystem Holdings, Inc. has an analysts' consensus of $14.20 which suggests that it could grow by 75.09%. Given that Catheter Precision, Inc. has higher upside potential than InfuSystem Holdings, Inc., analysts believe Catheter Precision, Inc. is more attractive than InfuSystem Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VTAKCatheter Precision, Inc.0 0 0 INFUInfuSystem Holdings, Inc.5 0 0 -
Is VTAK or INFU More Risky?
Catheter Precision, Inc. has a beta of -1.392, which suggesting that the stock is 239.195% less volatile than S&P 500. In comparison InfuSystem Holdings, Inc. has a beta of 1.680, suggesting its more volatile than the S&P 500 by 68.01%.
-
Which is a Better Dividend Stock VTAK or INFU?
Catheter Precision, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystem Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catheter Precision, Inc. pays -- of its earnings as a dividend. InfuSystem Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VTAK or INFU?
Catheter Precision, Inc. quarterly revenues are $226K, which are smaller than InfuSystem Holdings, Inc. quarterly revenues of $36.5M. Catheter Precision, Inc.'s net income of -$2.3M is lower than InfuSystem Holdings, Inc.'s net income of $2.3M. Notably, Catheter Precision, Inc.'s price-to-earnings ratio is 0.40x while InfuSystem Holdings, Inc.'s PE ratio is 31.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catheter Precision, Inc. is 9.83x versus 1.22x for InfuSystem Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VTAKCatheter Precision, Inc.9.83x 0.40x $226K -$2.3M INFUInfuSystem Holdings, Inc.1.22x 31.01x $36.5M $2.3M
-
Which has Higher Returns VTAK or PMI?
Picard Medical has a net margin of -1037.17% compared to Catheter Precision, Inc.'s net margin of --. Catheter Precision, Inc.'s return on equity of -192.05% beat Picard Medical's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital VTAKCatheter Precision, Inc.-141.59% -$1.70 $21.3M PMIPicard Medical-- -- -- -
What do Analysts Say About VTAK or PMI?
Catheter Precision, Inc. has a consensus price target of --, signalling upside risk potential of 1718.24%. On the other hand Picard Medical has an analysts' consensus of -- which suggests that it could fall by --. Given that Catheter Precision, Inc. has higher upside potential than Picard Medical, analysts believe Catheter Precision, Inc. is more attractive than Picard Medical.
Company Buy Ratings Hold Ratings Sell Ratings VTAKCatheter Precision, Inc.0 0 0 PMIPicard Medical0 0 0 -
Is VTAK or PMI More Risky?
Catheter Precision, Inc. has a beta of -1.392, which suggesting that the stock is 239.195% less volatile than S&P 500. In comparison Picard Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock VTAK or PMI?
Catheter Precision, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Picard Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catheter Precision, Inc. pays -- of its earnings as a dividend. Picard Medical pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VTAK or PMI?
Catheter Precision, Inc. quarterly revenues are $226K, which are larger than Picard Medical quarterly revenues of --. Catheter Precision, Inc.'s net income of -$2.3M is higher than Picard Medical's net income of --. Notably, Catheter Precision, Inc.'s price-to-earnings ratio is 0.40x while Picard Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catheter Precision, Inc. is 9.83x versus -- for Picard Medical. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VTAKCatheter Precision, Inc.9.83x 0.40x $226K -$2.3M PMIPicard Medical-- -- -- --
-
Which has Higher Returns VTAK or VNRX?
VolitionRX Ltd. has a net margin of -1037.17% compared to Catheter Precision, Inc.'s net margin of -862.39%. Catheter Precision, Inc.'s return on equity of -192.05% beat VolitionRX Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital VTAKCatheter Precision, Inc.-141.59% -$1.70 $21.3M VNRXVolitionRX Ltd.50.73% -$0.05 -$24.7M -
What do Analysts Say About VTAK or VNRX?
Catheter Precision, Inc. has a consensus price target of --, signalling upside risk potential of 1718.24%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 746.15%. Given that Catheter Precision, Inc. has higher upside potential than VolitionRX Ltd., analysts believe Catheter Precision, Inc. is more attractive than VolitionRX Ltd..
Company Buy Ratings Hold Ratings Sell Ratings VTAKCatheter Precision, Inc.0 0 0 VNRXVolitionRX Ltd.4 2 0 -
Is VTAK or VNRX More Risky?
Catheter Precision, Inc. has a beta of -1.392, which suggesting that the stock is 239.195% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.404%.
-
Which is a Better Dividend Stock VTAK or VNRX?
Catheter Precision, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catheter Precision, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VTAK or VNRX?
Catheter Precision, Inc. quarterly revenues are $226K, which are smaller than VolitionRX Ltd. quarterly revenues of $627.3K. Catheter Precision, Inc.'s net income of -$2.3M is higher than VolitionRX Ltd.'s net income of -$5.4M. Notably, Catheter Precision, Inc.'s price-to-earnings ratio is 0.40x while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catheter Precision, Inc. is 9.83x versus 17.82x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VTAKCatheter Precision, Inc.9.83x 0.40x $226K -$2.3M VNRXVolitionRX Ltd.17.82x -- $627.3K -$5.4M
-
Which has Higher Returns VTAK or XTNT?
Xtant Medical Holdings, Inc. has a net margin of -1037.17% compared to Catheter Precision, Inc.'s net margin of 3.93%. Catheter Precision, Inc.'s return on equity of -192.05% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.
Company Gross Margin Earnings Per Share Invested Capital VTAKCatheter Precision, Inc.-141.59% -$1.70 $21.3M XTNTXtant Medical Holdings, Inc.66.13% $0.01 $82.9M -
What do Analysts Say About VTAK or XTNT?
Catheter Precision, Inc. has a consensus price target of --, signalling upside risk potential of 1718.24%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 136.22%. Given that Catheter Precision, Inc. has higher upside potential than Xtant Medical Holdings, Inc., analysts believe Catheter Precision, Inc. is more attractive than Xtant Medical Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VTAKCatheter Precision, Inc.0 0 0 XTNTXtant Medical Holdings, Inc.2 0 0 -
Is VTAK or XTNT More Risky?
Catheter Precision, Inc. has a beta of -1.392, which suggesting that the stock is 239.195% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.077, suggesting its less volatile than the S&P 500 by 107.701%.
-
Which is a Better Dividend Stock VTAK or XTNT?
Catheter Precision, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catheter Precision, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VTAK or XTNT?
Catheter Precision, Inc. quarterly revenues are $226K, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Catheter Precision, Inc.'s net income of -$2.3M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Catheter Precision, Inc.'s price-to-earnings ratio is 0.40x while Xtant Medical Holdings, Inc.'s PE ratio is 62.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catheter Precision, Inc. is 9.83x versus 0.69x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VTAKCatheter Precision, Inc.9.83x 0.40x $226K -$2.3M XTNTXtant Medical Holdings, Inc.0.69x 62.25x $33.3M $1.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.7T
P/E Ratio: 65x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Buy
72
BNAI alert for Jan 29
Brand Engagement Network, Inc. [BNAI] is down 16.89% over the past day.
Buy
82
STX alert for Jan 29
Seagate Technology Holdings Plc [STX] is up 0.83% over the past day.
Buy
84
GDXU alert for Jan 29
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 12.19% over the past day.
